Paper Details

  1. Home
  2. Paper Details

A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.

Author: BoddyAlexander, DiMarcoJohn P, EllenbogenKenneth A, EzekowitzMichael D, GebaGregory P, KaszalaKaroly, KorenAndrew, PGregory Geba

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy of dronedarone in atrial fibrillation patients using dual-chamber pacemakers.
Paper Details　
Original Abstract of the Article :
Dronedarone is a benzofuran derivative with a pharmacological profile similar to amiodarone but has a more rapid onset of action and a much shorter half-life (13-19 h). Our goal was to evaluate the efficacy of dronedarone in atrial fibrillation (AF) patients using dual-chamber pacemakers capable of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346668/

データ提供：米国国立医学図書館（NLM）

Dronedarone: A New Hope for Atrial Fibrillation

The field of cardiology is constantly seeking new and effective treatments for atrial fibrillation (AF), a common heart rhythm disorder. This randomized controlled trial investigates the efficacy of dronedarone, a benzofuran derivative with a pharmacological profile similar to amiodarone, in reducing AF burden in patients with permanent pacemakers. The study utilizes a placebo-controlled, double-blind design to assess the effects of dronedarone compared to a placebo.

Dronedarone: A Potential Treatment for Atrial Fibrillation

The study's findings suggest that dronedarone may be a promising treatment option for AF. The results indicate that dronedarone significantly reduced AF burden compared to placebo in patients with permanent pacemakers. This suggests that dronedarone could be a valuable tool for managing AF and improving quality of life for patients with this condition.

A New Frontier in AF Management

This research provides a compelling case for further investigation of dronedarone as a treatment for AF. The authors encourage larger-scale clinical trials to confirm these findings and explore the long-term safety and efficacy of dronedarone in managing AF. This research represents a significant step forward in the search for effective and safe treatments for this common and often debilitating heart rhythm disorder.

Dr.Camel's Conclusion

This research, like a camel carrying a precious cargo across a vast desert, holds the promise of a new and effective treatment for AF. It reminds us that the journey toward better heart health is ongoing, and dronedarone represents a potentially valuable tool in our arsenal against this challenging condition. As we continue to explore new therapies for AF, we can hope for a future where patients experience fewer disruptions to their daily lives and enjoy a better quality of life.

Date :
  1. Date Completed 2016-04-22
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

25638303

DOI: Digital Object Identifier

PMC4346668

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.